TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
LONA

LeonaBio, Inc.

Healthcare · Biotechnology

5.60$ +15.8% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

LeonaBio, Inc. (LONA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 57 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet LONA
Line item Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
– – – 2.2 – 87 268 280 369 360 347 332 313 292 274 258 233 208 185 160 133 111 86 59 44 36 30 92 72 57
4.8 – – 2.2 2.1 86 232 192 312 290 239 261 269 256 229 208 193 192 179 155 129 107 82 55 40 32 27 89 69 55
-4.8 – – 2.1 -2.1 85 166 61 128 132 107 111 118 95 87 96 105 114 110 91 78 74 69 48 26 20 21 69 33 32
4.8 – – 2.1 2.1 85 226 185 304 285 236 254 264 252 221 200 186 186 173 147 122 92 69 51 37 30 25 88 68 51
– – – 0.0 – 0.0 – 1.3 2.9 2.6 2.1 2.3 2.2 – 1.7 1.2 – – – 1.6 1.6 1.6 1.6 – – – – – – –
– – – 22 – 6.9 8.5 5.3 6.2 9.4 11 11 11 11 12 23 22 23 30 30 27 28 29 14 6.2 3.6 3.2 64 22 23
– – – 1.3 – 5.5 7.6 4.4 4.5 7.6 9.4 9.3 9.5 9.7 10 21 20 22 29 29 26 27 28 13 5.5 3.0 2.8 48 6.7 7.8
– – – – – – 0.1 0.1 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.5 0.5
– – – 0.4 – 4.3 3.9 1.2 1.7 1.2 1.0 0.6 1.4 0.6 0.8 2.5 0.9 0.6 1.7 0.1 0.7 0.5 0.4 0.3 0.9 0.2 0.3 4.6 1.8 2.4
2.2 – – -20 -2.7 80 259 274 363 351 336 321 302 281 262 235 211 185 155 130 107 83 58 45 37 32 27 28 49 34
– – – -21 – -25 -33 -41 -50 -64 -80 -96 -117 -141 -161 -192 -219 -249 -282 -309 -336 -362 -391 -406 -415 -422 -429 -512 -545 -564
0.4 0.4 3.1 3.3 3.3 3.3 3.1 3.2 3.6 3.7 3.7 3.7 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.8 3.9 3.8 3.9 3.9 3.9 4.3 4.3 4.3

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?